Free Trial
NASDAQ:PASG

Passage Bio Q2 2023 Earnings Report

Passage Bio logo
$0.43 -0.01 (-3.17%)
As of 11:37 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Passage Bio EPS Results

Actual EPS
-$0.44
Consensus EPS
-$0.47
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Passage Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Passage Bio Announcement Details

Quarter
Q2 2023
Time
Q2 2023 Earnings Release
Conference Call Date
Monday, August 7, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Passage Bio's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 7:15 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Passage Bio Earnings Headlines

Passage Bio Announces 1-for-20 Reverse Stock Split
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
PASG Passage Bio, Inc. - Seeking Alpha
See More Passage Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Passage Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Passage Bio and other key companies, straight to your email.

About Passage Bio

Passage Bio (NASDAQ:PASG) is a clinical-stage biotechnology company specializing in the development of gene therapies for rare monogenic diseases of the central nervous system. Leveraging a proprietary adeno-associated virus (AAV) platform, the company focuses on delivering functional copies of disease-causing genes directly to affected tissues. Its research activities center on addressing unmet medical needs in genetic disorders where conventional treatments are limited or nonexistent.

The company’s lead programs target GM1 gangliosidosis and Tay-Sachs disease, both fatal neurodegenerative conditions arising from enzyme deficiencies. In parallel, Passage Bio is advancing preclinical candidates for GM2 gangliosidosis, Krabbe disease and Alexander disease. By collaborating with academic institutions and patient advocacy groups, the company conducts natural history studies, refines dosing strategies and accelerates regulatory pathways to facilitate clinical development.

Founded in 2019 as a spin-out from the Gene Therapy Program at Children’s Hospital of Philadelphia and the University of Pennsylvania, Passage Bio has established its headquarters in Philadelphia, Pennsylvania. The company operates a research facility in the greater Philadelphia area and engages with global experts in gene therapy from leading academic medical centers. Through partnerships and grant collaborations, Passage Bio extends its reach to international research communities and patient networks.

Under the leadership of President and Chief Executive Officer Paul R. Miller, Passage Bio’s executive team combines expertise in neurology, molecular biology and regulatory affairs. The company’s board of directors includes seasoned professionals from both biotech and pharmaceutical industries, guiding strategic decisions and supporting the advancement of its gene therapy portfolio. Passage Bio remains committed to pioneering durable treatments for patients facing devastating genetic disorders.

View Passage Bio Profile

More Earnings Resources from MarketBeat